查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1464782

双特异性抗体市场：按作用机制、治疗领域和最终用户 - 2024-2030 年全球预测

Bispecific Antibodies Market by Mechanism of Action (Dual Antigen Targeting, Dual-Blocking Antibodies, T-cell Engagers), Therapeutic Area (Autoimmune Diseases, Infectious Diseases, Neurological Disorders), End-user - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

双特异性抗体市场规模预计2023年为43.6亿美元，2024年达到61.4亿美元，预计2030年将达到514.7亿美元，复合年增长率为42.24%。

双特异性抗体 (BsAb) 是一种工程蛋白，可同时结合两种不同类型的抗原或同一抗原上的两个不同表位。这种双标靶能力使它们有别于传统的单株抗体，传统的单株抗体是为了结合单一抗原而开发的。双特异性抗体的主要用途是在治疗领域，特别是针对和中和癌细胞。其独特的能力使效应细胞更接近癌细胞，从而增强免疫系统对抗癌症的能力。此外，它在研究中了解疾病机制的用途与其在开发更有效的自体免疫和发炎疾病治疗方法中的应用进一步一致。全球癌症和其他慢性疾病发病率的上升、基因和蛋白质工程技术的进步以及开发和核准新型双特异性抗体的创新推动了双特异性抗体市场的增长，其中包括对治疗方法的监管支持不断增加。然而，双特异性抗体的扩展受到开发双特异性抗体的高成本和生产双特异性抗体的复杂性的阻碍。同时，越来越多地使用双特异性抗体来治疗罕见疾病，以及製药公司对医疗基础设施和研发活动的投资增加，正在为双特异性抗体市场开闢新的途径。

主要市场统计
基准年[2023] 43.6亿美元
预测年份 [2024] 61.4亿美元
预测年份 [2030] 514.7亿美元
复合年增长率（%） 42.24%

作用机转：增加对双抗原标靶的偏好，以尽量减少脱靶效应

双抗原靶向双特异性抗体旨在同时结合细胞表面上的两种不同抗原。该机制透过确保标靶必须存在才能结合来提高选择性和功效，从而最大限度地减少脱靶效应并改善治疗结果。它是癌症等复杂疾病所必需的，其中多种途径驱动疾病进展。双重阻断抗体同时抑制两种不同讯号传导途径的作用。透过抑制两种不同的配体或受体，这些抗体可以更有效地阻断病理过程，特别是在癌症和自体免疫疾病等疾病中。在讯号途径冗余损害单一标靶药物功效的情况下，基于需求的双阻断抗体偏好变得明显。 T 细胞接合剂是双特异性抗体的一个子集，旨在使细胞毒性 T 细胞靠近癌细胞，促进肿瘤的靶向杀伤。在肿瘤学领域，基于需求的 T 细胞参与者偏好尤其强烈，利用患者的免疫系统来对抗癌症的能力可显着改善治疗结果。与这些机制相比，针对双抗原的双特异性抗体具有选择性增加的优点，特别适合具有明确特征和特异性病理标记的疾病。透过靶向多种途径，双抗原阻断抗体有望改善以途径冗余和补偿疾病进展机制为特征的疾病的治疗结果。 T 细胞接合剂提供了一种独特的方法，透过招募免疫系统来对抗肿瘤，并在肿瘤学方面显示出巨大的潜力，但潜在的免疫介导的毒性需要仔细管理。

治疗领域：扩大双特异性抗体在癌症领域的应用，旨在接触和破坏癌细胞

双特异性抗体的双靶向能力提供了一种强大的机制来攻击和破坏癌细胞，同时保护健康组织。双特异性抗体在肿瘤学中的应用范围广泛，从标靶化肿瘤抗原到让免疫效应细胞参与更定向的针对癌症的免疫反应。在自体免疫疾病中，双特异性抗体（bsAb）代表了一种有前途的标靶免疫治疗方法。这些分子经过定制，可同时结合两种不同的抗原或表位，精确调节免疫反应。需要实现选择性免疫抑製而不具有广泛的免疫抑製作用并降低感染疾病和恶性的风险。双特异性抗体作用于多个标靶的独特能力有可能对抗感染疾病，特别是包括爱滋病毒在内的病毒感染疾病，其中逃避免疫系统是一个关键挑战。这些治疗方法可以透过同时针对病毒表位和招募免疫细胞来增强抗病毒反应。双特异性抗体能够精确靶向神经抗原并促进穿过血脑障壁（BBB），这是神经治疗的关键挑战，为神经疾病的治疗提供了新途径。在癌症领域，临床开发的双特异性抗体应用最为先进，种类繁多。这是由于对标靶癌症治疗的高需求以及该领域的大量投资。与传统治疗方法相比，双特异性抗体可在自体免疫和神经系统疾病领域提供新颖的作用机制。目前针对感染疾病开发的双特异性抗体很少，它们代表了一种潜在的突破性治疗方法，特别是对于对标准治疗有抵抗力的慢性病毒感染疾病。

区域洞察

在强大的研发基础设施、大量的医疗保健支出和强大的专利组合的支持下，美国处于市场需求和双特异性抗体开发的前沿。 FDA 的支持性法律规范加速了创新治疗方法的核准，并鼓励对专门从事双特异性抗体的生物技术公司进行大量投资。在加拿大，人们对双特异性抗体疗法的兴趣日益浓厚，研究机构和生物技术新兴企业获得了政府和私人资助。儘管南美双特异性抗体市场仍处于发展阶段，但医疗保健支出的增加、创新癌症治疗意识的增强以及医疗基础设施的改善正在推动该地区的市场扩张，显示出巨大的成长潜力。在欧盟，重点放在引进先进的治疗解决方案，包括双特异性抗体。新治疗方法的核准、高昂的医疗费用以及欧洲药品管理局 (EMA) 提高患者意识的积极措施正在为 BsAb 创造有利的环境。双特异性抗体在中东和非洲的采用进展缓慢，主要是由于卫生基础设施有限和卫生支出较低。然而，阿联酋和沙乌地阿拉伯等中东国家正在医疗保健领域取得长足进步，这可能为双特异性抗体市场提供动力。亚太地区双特异性抗体市场正在显着成长。这是由于医疗费用飙升、癌症发病率上升以及人们对先进治疗的认识不断增强。中国和日本处于双特异性抗体研发的前沿。监管改革、医疗基础设施的扩张以及本地生物技术公司与国际製药巨头之间的联盟是推动亚太市场的关键因素。

FPNV定位矩阵

FPNV定位矩阵对于评估双特异性抗体市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对双特异性抗体市场供应商的现状进行深入而详细的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1. 双特异性抗体市场规模及预测如何？

2.双特异性抗体市场预测期间需要考虑投资的产品、细分市场、应用和领域有哪些？

3. 双特异性抗体市场的技术趋势和法规结构是什么？

4.双特异性抗体市场主要厂商的市场占有率为何？

5. 进入双特异性抗体市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地癌症和其他慢性病的发生率正在上升
      • 基因工程和蛋白质工程技术进展
      • 扩大对创新治疗方法的监管支持，以促进新型双特异性抗体的开发和核准
    • 抑制因素
      • 开发双特异性抗体成本高
    • 机会
      • 扩大双特异性抗体在罕见疾病治疗的应用
      • 製药公司增加对医疗保健基础设施和研发活动的投资
    • 任务
      • 与双特异性抗体相关的製造复杂性
  • 市场区隔分析
    • 作用机转：双抗原标靶化优先以最大限度地减少脱靶效应
    • 治疗领域：扩大双特异性抗体在肿瘤学的应用，攻击并破坏癌细胞
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章双特异性抗体市场：按作用机制

  • 双抗原靶点
  • 双抑制抗体
  • T 细胞接合器

第七章双特异性抗体市场：依治疗领域

  • 自体免疫疾病
  • 感染疾病
  • 神经系统疾病
  • 肿瘤学

第 8 章双特异性抗体市场：依最终用户分类

  • 医院和专家
  • 研究机构和学术中心

第九章美洲双特异性抗体市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太双特异性抗体市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲双特异性抗体市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 市场占有率分析（2023）
  • FPNV定位矩阵（2023）
  • 竞争情境分析
    • 阿斯特捷利康共用双特异性资料，目标是「2.0」癌症管道
    • 美国FDA核准双特异性疗法 TALVEY(TM) (talketamab-TGV) 用于治疗曾接受严重治疗的多发性骨髓瘤患者
    • 辉瑞的 erlanatamab 获得 FDA 和 EMA 提交接受
  • 战略分析和建议

第13章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-F97DD5A7DF65

[192 Pages Report] The Bispecific Antibodies Market size was estimated at USD 4.36 billion in 2023 and expected to reach USD 6.14 billion in 2024, at a CAGR 42.24% to reach USD 51.47 billion by 2030.

Bispecific antibodies (BsAbs) are engineered proteins that can simultaneously attach to two different types of antigens or two different epitopes on the same antigen. This dual-targeting ability distinguishes them from traditional monoclonal antibodies developed to bind to a single antigen. The primary applications of bispecific antibodies reside in the therapeutic domain, particularly in targeting and neutralizing cancer cells. Their unique capability allows them to bring effector cells in close proximity to cancer cells, enhancing the immune system's ability to combat cancer. Additionally, their use in research to understand disease mechanisms further aligns with their application in creating more effective treatments for autoimmune and inflammatory diseases. Several factors contribute to the growth of the bispecific antibodies market, including rising incidences of cancer and other chronic illnesses globally, advancements in genetic engineering and protein engineering technologies, and growing regulatory support for innovative therapies for developing and approving novel bispecific antibodies. However, the expansion of bispecific antibodies is hindered by the high costs of the development of bispecific antibodies and the manufacturing complexities associated with bispecific antibodies. On the other hand, expanding usage of bispecific antibodies in the treatment of rare diseases and rising investments in healthcare infrastructure and research & development activities by pharmaceutical companies opens new avenues for the bispecific antibodies market.

KEY MARKET STATISTICS
Base Year [2023] USD 4.36 billion
Estimated Year [2024] USD 6.14 billion
Forecast Year [2030] USD 51.47 billion
CAGR (%) 42.24%

Mechanism of Action: Increasing preference for dual antigen targeting for minimizing off-target effects

Dual antigen-targeting bispecific antibodies are designed to bind to two distinct antigens on the surface of cells simultaneously. This mechanism enhances selectivity and efficacy by ensuring that targets must be present for binding, thereby minimizing off-target effects and improving therapeutic outcomes. It is needed in complex diseases, including cancer, where multiple pathways drive disease progression. Dual-blocking antibodies inhibit the action of two separate signaling pathways simultaneously. By blocking two different ligands or receptors, these antibodies can more effectively shut down pathological processes, especially in diseases such as cancer and autoimmune disorders. Need-based preference for dual-blocking antibodies becomes apparent in conditions where redundancy in signaling pathways can undermine the efficacy of single-target agents. T-cell engagers represent a subset of bispecific antibodies designed to bring cytotoxic T-cells into close proximity with tumor cells, thereby promoting the targeted killing of the tumor. Need-based preference for T-cell engagers is particularly strong in oncology, where the ability to harness the patient's immune system to fight cancer can significantly improve outcomes. In comparing these mechanisms, dual antigen-targeting bsAbs offer the advantage of enhanced selectivity, making them particularly suitable for diseases with well-characterized and specific pathological markers. Dual-blocking antibodies, by targeting multiple pathways, promise improved therapeutic outcomes in diseases characterized by pathway redundancy or compensatory mechanisms of disease progression. T-cell engagers offer a unique approach by mobilizing the immune system against tumors, showing great promise in oncology but requiring careful management of potential immune-mediated toxicities.

Therapeutic Area: Expanding application of bispecific antibodies in oncology for engaging and destroying cancer cells

Oncology remains the most prolific area for the application of bispecific antibodies, with their dual-targeting ability offering a potent mechanism for engaging and destroying cancer cells while sparing healthy tissue. The use of bsAbs in oncology spans targeting tumor antigens to engaging immune effector cells for a more directed immune response against cancer. In autoimmune diseases, bispecific antibodies (bsAbs) pose a promising approach for targeted immunotherapy. These molecules are tailored to bind two different antigens or epitopes simultaneously, allowing precision in modulating immune responses. The need lies in achieving selective immunosuppression without broad immunosuppressive effects, thus reducing the risk of infections and malignancies. The unique capability of bispecific antibodies to engage multiple targets holds potential in combating infectious diseases, particularly viral infections, including HIV, where evasion of the immune system is a significant challenge. These therapies can simultaneously target viral epitopes and recruit immune cells, thereby enhancing the antiviral response. Bispecific antibodies offer a novel pathway in treating neurological disorders by enabling precise targeting of neural antigens and facilitating the cross of the blood-brain barrier (BBB), a significant challenge in neurotherapeutics. The oncology sector exhibits the most advanced application and diverse range of bsAbs under clinical development, which is attributed to the high need for targeted cancer therapies and the significant investment in this area. Autoimmune diseases and neurological disorders represent growing segments where bsAbs can offer novel mechanisms of action compared to traditional therapies. Infectious diseases currently have fewer bsAbs under development and show potential for groundbreaking therapies, especially in chronic viral infections resistant to standard treatment.

Regional Insights

The United States is at the forefront of the market demand and the development of bispecific antibodies, backed by robust R&D infrastructure, significant healthcare spending, and a strong patent portfolio. The FDA's supportive regulatory framework accelerates the approval of innovative therapies, encouraging substantial investments in biotechnology firms focused on BsAbs. Canada showcases a growing interest in bispecific antibody therapies, with research institutions and biotech startups receiving government and private funding. The South American market for bispecific antibodies is in a nascent stage; however, it exhibits potential for significant growth due to increasing healthcare expenditure, rising awareness about innovative cancer treatments, and improving healthcare infrastructure, contributing to the market expansion in this region. In the European Union, there's a strong emphasis on the adoption of advanced therapeutic solutions, including bispecific antibodies. The EMA's (European Medicines Agency) proactive approach to approving novel treatments and high healthcare expenditure and patient awareness fosters a favorable environment for BsAbs. The Middle East and Africa show a slower adoption of bispecific antibodies, primarily due to limited healthcare infrastructure and lower healthcare spending. However, certain countries in the Middle East, such as UAE and Saudi Arabia, are making strides in the healthcare sector, which could provide an impetus to the bispecific antibodies market. The APAC region is witnessing remarkable growth in the bispecific antibodies market, driven by escalating healthcare expenditure, rising cancer incidence, and growing awareness about advanced therapies. China and Japan are at the forefront, spearheading research and development in the bispecific antibodies. Regulatory reforms, expanding healthcare infrastructures, and partnerships between local biotech firms and international pharmaceutical giants are key factors propelling the market in APAC.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Bispecific Antibodies Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Bispecific Antibodies Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Bispecific Antibodies Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adimab, LLC, Affimed GmbH, Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Eli Lilly and Company, Emergent BioSolutions Inc., F. Hoffmann-La Roche Ltd., Genmab A/S, Gilead Sciences, Inc., Innovent Biologics, Janssen Global Services, LLC by Johnson & Johnson Pte. Ltd., MacroGenics, Inc., Merck KGaA, Mereo Biopharma Group PLC, Merus N.V., Novartis AG, Pfizer Inc., Pieris Pharmaceuticals, Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., TG Therapeutics, Inc., and Xencor, Inc..

Market Segmentation & Coverage

This research report categorizes the Bispecific Antibodies Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Mechanism of Action
    • Dual Antigen Targeting
    • Dual-Blocking Antibodies
    • T-cell Engagers
  • Therapeutic Area
    • Autoimmune Diseases
    • Infectious Diseases
    • Neurological Disorders
    • Oncology
  • End-user
    • Hospitals & Specialist Clinics
    • Research Institutions & Academic Centers
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Bispecific Antibodies Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Bispecific Antibodies Market?

3. What are the technology trends and regulatory frameworks in the Bispecific Antibodies Market?

4. What is the market share of the leading vendors in the Bispecific Antibodies Market?

5. Which modes and strategic moves are suitable for entering the Bispecific Antibodies Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of cancer and other chronic illnesses globally
      • 5.1.1.2. Advancements in genetic engineering and protein engineering technologies
      • 5.1.1.3. Growing regulatory support for innovative therapies for the development and approval of novel bispecific antibodies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost regarding the development of bispecific antibodies
    • 5.1.3. Opportunities
      • 5.1.3.1. Expanding usage of bispecific antibodies in the treatment of rare diseases
      • 5.1.3.2. Rising investments in healthcare infrastructure and research & development activities by pharmaceutical companies
    • 5.1.4. Challenges
      • 5.1.4.1. Manufacturing complexities associated with bispecific antibodies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Mechanism of Action: Increasing preference for dual antigen targeting for minimizing off-target effects
    • 5.2.2. Therapeutic Area: Expanding application of bispecific antibodies in oncology for engaging and destroying cancer cells
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Bispecific Antibodies Market, by Mechanism of Action

  • 6.1. Introduction
  • 6.2. Dual Antigen Targeting
  • 6.3. Dual-Blocking Antibodies
  • 6.4. T-cell Engagers

7. Bispecific Antibodies Market, by Therapeutic Area

  • 7.1. Introduction
  • 7.2. Autoimmune Diseases
  • 7.3. Infectious Diseases
  • 7.4. Neurological Disorders
  • 7.5. Oncology

8. Bispecific Antibodies Market, by End-user

  • 8.1. Introduction
  • 8.2. Hospitals & Specialist Clinics
  • 8.3. Research Institutions & Academic Centers

9. Americas Bispecific Antibodies Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Bispecific Antibodies Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Bispecific Antibodies Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. AstraZeneca aims for '2.0' cancer pipeline, shares bispecific data
    • 12.3.2. U.S. FDA Approves TALVEY(TM) (talquetamab-tgvs), a Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma
    • 12.3.3. Pfizer's Elranatamab Receives FDA and EMA Filing Acceptance
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. BISPECIFIC ANTIBODIES MARKET RESEARCH PROCESS
  • FIGURE 2. BISPECIFIC ANTIBODIES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. BISPECIFIC ANTIBODIES MARKET DYNAMICS
  • FIGURE 7. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. BISPECIFIC ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. BISPECIFIC ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BISPECIFIC ANTIBODIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY DUAL ANTIGEN TARGETING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY DUAL ANTIGEN TARGETING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY DUAL-BLOCKING ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY DUAL-BLOCKING ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY T-CELL ENGAGERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY T-CELL ENGAGERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY HOSPITALS & SPECIALIST CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY HOSPITALS & SPECIALIST CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY RESEARCH INSTITUTIONS & ACADEMIC CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY RESEARCH INSTITUTIONS & ACADEMIC CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 32. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 33. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 34. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 35. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 36. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 37. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 38. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 39. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 40. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 41. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 42. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 43. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 44. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 45. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 46. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 47. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 48. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 49. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 50. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 51. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 52. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 53. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 54. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 55. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 56. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 57. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 58. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 59. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 60. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 61. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 62. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 63. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 64. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 65. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 66. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 67. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 68. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 69. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 70. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 80. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 82. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 84. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 85. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 86. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 87. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 88. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 89. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 90. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 91. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 92. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 93. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 94. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 95. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 96. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 97. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 98. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 99. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 100. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 101. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 102. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 103. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 104. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 105. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 106. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 107. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 108. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 109. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 110. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 111. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 112. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 113. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 114. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 116. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 118. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 120. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 121. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 122. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 123. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 124. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 125. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 126. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 128. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 130. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 132. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 133. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 134. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 135. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 136. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 137. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 138. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 139. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 140. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 141. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 142. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 143. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 144. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 145. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 146. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 147. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 148. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 149. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 150. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 159. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 160. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 161. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 162. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 163. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 164. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 165. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 166. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 167. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 168. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 169. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 170. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 171. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 172. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 173. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 174. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 175. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 176. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 177. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 178. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 179. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 180. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 181. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 182. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 183. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 184. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 185. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 186. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 187. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 188. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 189. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 190. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 191. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 192. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 193. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 194. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 195. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 196. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 197. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 198. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 199. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 200. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 202. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 204. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 206. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 207. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 208. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 209. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 210. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 211. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 212. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 213. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 214. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 215. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 216. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 217. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 218. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 219. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 220. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 221. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 222. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 223. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 224. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 225. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 226. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 227. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 228. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 229. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 230. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 231. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 232. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 233. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 234. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 235. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 236. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 238. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 240. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 242. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 244. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 246. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 248. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 249. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 250. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 251. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 252. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 253. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 254. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 255. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 256. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 257. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 258. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 259. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 260. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 262. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 264. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 266. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 267. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 268. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 269. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 270. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 271. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 272. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
  • TABLE 280. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
  • TABLE 282. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 284. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 285. BISPECIFIC ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 286. BISPECIFIC ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023